title: [Expression of Fas ligand in urogenital malignant cell lines and renal cell carcinoma].
abstract: OBJECTIVE
  To explore the expression of Fas ligand in urogenital malignant cell lines and renal cell carcinoma.
  
  
  METHODS
  With immunocytochemistry and reverse transcription-polymerase chain reaction (RT-PCR), we detected the expression of Fas ligand (FasL) in 6 urogenital malignant cell lines, bladder carcinoma cell lines (T(24), EJ, BIU-87), renal cell carcinoma cell lines (GRC-1, RCC-949), prostatic carcinoma cell line (PC-3M), and 10 cases of renal cell carcinoma.
  
  
  RESULTS
  The expression of FasL was detected in 3 (BIU-87, RCC-949, GRC-1) of the 6 urogenital malignant cell lines with immunocytochemistry, and 4 (BIU-87, RCC-949, GRC-1, PC-3M) of 6 urogenital malignant cell lines with RT-PCR method. No expression of FasL was detected in bladder carcinoma cell lines T(24) and EJ. Eight of 10 renal cell carcinoma tissues positively expressed FasL mRNA.
  
  
  CONCLUSIONS
  FasL can express in urogenital malignant cell lines and renal cell carcinoma.
authors.affiliation: Urological Department, First Hospital, Beijing Medical University, Beijing 100034, China.
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.forename: L
authors.initials: L
authors.lastname: Yu
authors.forename: Y
authors.initials: Y
authors.lastname: Guo
authors.forename: Y
authors.initials: Y
authors.lastname: Ding
authors.forename: L
authors.initials: L
authors.lastname: Liu
mesh_terms: D002292:Carcinoma, Renal Cell / Q000378:metabolism*; D045744:Cell Line, Tumor; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007680:Kidney Neoplasms / Q000378:metabolism*; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014565:Urogenital Neoplasms / Q000378:metabolism* / Q000473:pathology
chemical_list: C505661:FASLG protein, human; D053222:Fas Ligand Protein; D008562:Membrane Glycoproteins